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Abstract: 
 
Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic 
agent recently introduced for the management of upper gastrointestinal bleeding 
(GIB). To date, small experience exists with this fairly new hemostatic tool. The aim 
of this case series was to reflect the use and effectiveness of Hemospray as 
treatment option in GIB in all-day clinical practise. Sixteen consecutive patients  with 
active GIB of various origins were treated with Hemospray. The rate of successful 
initial hemostasis was 93.75% (as salvage therapy success rate 92.85%; as 
monotherapy success rate 100%). The rebleeding rate within 7 days was 12.5%. 
Only one patient failed also interventional radiology and had to undergo surgery as 
salvage therapy.  
Effectiveness of Hemospray in the management of GIB in various clinical situations is 
promising. Future multicenter randomized prospective trials for clearly defined 
bleeding situations are needed to increase the generalizability of case series. 
 
Introduction  
 
Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a hemostatic 
inorganic agent. When in contact with moisture, Hemospray becomes coherent and 
adhesive, creating a mechanical barrier and effecting hemostasis. Hemospray was 
recently introduced for the management of upper gastrointestinal bleeding (GIB) [1]. 
In Europe, Hemospray is not licensed for use in the lower gastrointestinal (GI) tract 
and therefore currently in off-label use in the lower GI tract. So far, preliminary 
experience in benign and malignant upper and lower GIB is promising although 
limited [1-5]. However, optimal indications and technical limitations are still being 
characterized. We present our prospective case series from daily routine regarding 
Hemospray in the treatment of GIB in two tertiary endoscopy centres of Switzerland, 
adding to the increasing experience with this promising treatment modality. 
 
Case series  
 
Methods: From August 2013 until November 2013, consecutive patients with active 
bleedings of various origins in the upper and lower GI tract were treated with 
Hemospray in two tertiary endoscopy centres of Switzerland. Data on sex, age, 
medication, details of procedure, and outcome were collected prospectively. Approval 
to use pseudonymised patient data was obtained by the local Ethical committee. 
Endoscopic hemostatic interventions (using an Olympus 1TQ–scope; Olympus, 
Tokyo, Japan) were performed exclusively by eleven experienced staff endoscopists 
(eight endoscopists in St. Gallen, three endoscopists in Zurich) who underwent an 
official theoretical and practical training in Hemospray application organized by the 
Clinic of gastroenterology and hepatology, University hospital Zurich together with the 
company Cook. The training had to be passed before the first clinical application of 
each endoscopist.  
Criteria of utilization of Hemospray: Hemospray was used either as 
monotherapy or as salvage therapy at the discretion of the performing endoscopist. 
Following conditions were ideal to prefer Hemospray as first-line therapy over 
standard hemostatic methods: oozing bleeding from a malignant tumour; bleeding 
situations which involve larger areas of mucosa that are not well amenable to 
standard, targeted therapies (e.g. portal hypertensive gastropathy, gastric antral 
vascular ectasia).  
Technique of Hemospray application: Hemospray was applied on to the active 
bleeding site through a 10-Fr catheter (Cook Medical) in short bursts of a CO2-
propelled canister until hemostasis was confirmed. A burst on average contains 1-5 g 
of powder and lasts about one second. A maximum of 20 g (accords four bursts) was 
applied. The distal end of the catheter was placed 2 to 3 cm apart from the bleeding 
in order to prevent sticking the catheter in moisture. Video 1 shows the technique of 
Hemospray application. Successful initial hemostasis was defined when Hemospray 
application led to hemostasis after three to five minutes of visual inspection. Second 
look endoscopy was not performed in standardized regime, but only when rebleeding 
was assumed.  
Results: In both centers 194 patients presented with upper and lower GIB from 
August 2013 until November 2013. Of those 194 patients, 16 (8.25%) patients 
(81.25% males; median age 67 years (range 40-87 years)) with GIB were treated 
with Hemospray from August 2013 until November 2013. 13/16 (81.25%) patients 
had significant co-morbidities. 5/16 (31.25%) presented with shock, needing six 
packages of red cells in average. In all cases, a maximum of 20g (accords four 
bursts) of Hemospray was used. Details are shown in table 1. There was a variety of 
bleeding causes (Table 1 and 2). 25% of the patients suffered from ulcer disease. 
81.25% of cases were oozing bleedings. Figure 1 illustrates the hemostatic effect of 
Hemospray in a patient with oozing bleeding after percutaneous endoscopic 
gastrostomy tube insertion. Figure 2 and Video 1 show a spurting ulcer bleeding 
(Forrest Ia) in the duodenum. After failed hemostatic treatment, Hemospray 
application was successful. 
4/16 cases (25%) had preceding hemostatic endoscopic treatment in our centers 
within two days beforehand and therefore counted as re-bleedings or hemostatic 
failures for which repeated endoscopy was necessary. The remaining cases had no 
previous endoscopy. 14/16 (87.5% of cases) were treated with Hemospray as 
salvage therapy after failed hemostasis with standard methods such as injection, 
clipping, heater probe or argon plasma coagulation in the same endoscopic session 
(Table 1 and 2). In this group with Hemospray as salvage therapy, the rate of 
successful initial hemostasis was 92.85% (13/14) (Table 2). The rate of initial 
hemostasis with Hemospray as monotherapy was 100% (2/2) (Table 2). The 
rebleeding rate within 7 days was 12.5%. Both cases had prior oozing bleeding and 
needed repeated endoscopy within 24 hours (Table 2). One patient failed also 
interventional radiology and had to undergo surgery as salvage therapy (Table 1). 
Neither deaths occurred within 7 days after Hemospray application, nor was a CO2-
associated barotrauma noticed. 
 
Discussion 
 
In this patient series, the outcomes are presented for 16 consecutive patients with 
active upper and lower GIB who were treated with Hemospray in two high-volume 
tertiary centers in Switzerland. Our patient collective represents a typical distribution 
of bleeding causes in the daily routine of gastroenterologists who are on call for 
emergencies [7]. In expert hands, Hemospray is very effective in reaching initial 
hemostasis. Our series emphasizes the possible field of application of Hemospray in 
upper and lower GIB in all-day clinical practise. High efficacy in achieving initial 
hemostasis of non-variceal upper GIB through Hemospray is also shown by some 
case reports and small case series [1,2]. So far, only one small clinical prospective 
study was published that analysed the hemostatic effectiveness of Hemospray in 
actively bleeding ulcers (20 patients) [1]. Rebleeding appeared in 11% of 19 patients 
with oozing bleeding. Very recently, the first European prospective non-randomized 
multicentre SEAL survey (Survey to Evaluate the Application of Hemospray in the 
Luminal tract) with 63 patients was published as electronic version ahead of print [5]. 
In this survey, non-variceal upper GIB were analysed. The majority of patients (87%) 
were treated with Hemospray as monotherapy with a primary hemostasis rate of 85% 
and a rebleeding rate at 7 days of 15% [5]. 13% of patients were treated with 
Hemospray as salvage therapy with a hemostasis rate of 100% [5]. In our case 
series, exept in two cases, Hemospray was used as a salvage modality missing 
immediate success of conventional hemostatic methods. In this particular setting this 
new tool in the endoscopist’s armamentarium fulfills its purpose. Whether Hemospray 
may be an ideal first choice hemostatic tool and in which patients needs to be 
defined.  
In Europe, Hemospray is not licensed for use in the lower GI tract and is 
therefore currently in off-label use in the lower GI tract. The feasibility of Hemospray 
for colon application was demonstrated recently by Soulellis et al. [3] (case series 
with 5 patients) and Holster et al. [7] (case series with 9 patients). The preliminary 
experience from literature shows that Hemospray is a highly effective endoscopic 
hemostatic alternative in lower GIB [3,7]. In our series, one patient had bled from the 
lower GI tract, caused by a relapsing anal carcinoma. Hemospray was applied in 
addition to a surgical suture. So far no other reports in literature have mentioned this 
indication for Hemospray. 
Only preliminary data based on case reports exist regarding the off-label use 
of Hemospray for variceal bleeding [8,9]. Holster et al. [8] reported the first case of 
variceal bleeding refractory to standard endoscopic therapy, successfully treated with 
Hemospray, as a bridge towards transjugular intrahepatic portosystemic shunt 
procedure. So far, no potential complications (e.g. embolization of the powder) after 
the use of Hemospray in variceal bleeding is reported in literature. One patient with 
gastric varices in our series was treated successfully with Hemospray after Histoacryl 
insertion.  
A promising indication seems to be bleeding after sphincterotomy. In one of 
the two patients in our series hemostasis of a spurting sphincterotomy bleeding was 
difficult, finally success was achieved after combined use of heater probe, 
CoagGrasper, epinephrine injection, Hemospray and insertion of a fully covered 
metal stent. Moosavi et al. [10] published a case with transient obstruction of a post-
sphincterotomy biliary orifice after Hemospray application. Technically, Hemospray 
application for bleeding in and around the papilla Vateri is challenging. Maneuvers 
with the endoscope in the narrow lumen during ongoing bleeding may bring the 
application catheter unintentionally in contact with moisture, which sticks the distal 
end of the catheter and makes spraying impossible. 
Some limitations need to be mentioned. First, our series is limited by the small 
number of patients and also the diversity of indications for therapy. Second , patients 
treated in a tertiary endoscopy center are usually not comparable with patients in 
district hospitals. This means a selectional bias. Third, the decision to apply 
Hemospray or not was at the discretion of the endoscopist being subjective and not 
reproducible. Exact criteria when to use or not to use Hemospray as the first line 
agent, were not defined before starting this study. Anyhow all experienced 
endoscopists trained in endoscopic hemostasis, never used Hemospray in standard 
situations as first attempt. In this context it needs to be mentioned that Over-The-
Scope-Clip (OTSC, OVESCO, Tübingen, Germany) application is also known as a 
new endoscopic hemostatic tool. We are still somewhat reluctant to apply OTSC in 
bleeding situations because it is an implant material that usually stays for indefinite 
time. In our study many endoscopists performed Hemospray application with a good 
success rate. Hemospray application can be learned easy and quickly without a long 
learning curve which is certainly a strength of this new hemostatic tool. Therefore we 
prefer Hemospray over OTSC. In addition an OTSC could be applied subsequently if 
Hemospray fails. However, to date there are no data available that compared 
Hemospray versus OTSC. Fourth, the use of anti-thrombotics in our collective 
appears relatively low in respect of the included population (mean age 67 years). We 
speculate that one reason could be that our patients had many co-morbidities 
(according ASA classification III and IV, 62.5 and 18.75%, respectively). At the time 
of bleeding, the majority of patients was already hospitalized for (at least some) days, 
and the treating medical team stopped Aspirin or Clopidogrel beforehand due to the 
life-threatening bleeding situation. The initially healthy patients (ASA I and II) had no 
anti-thrombotics. 
In conclusion, Hemospray in the management of upper and also lower GIB is 
promising. Hemospray is a welcome hemostatic modality that can be used either 
instead of the current treatment modalities, but also as salvage therapy after failure of 
usual modalities. The non-contact nature of Hemospray makes it desirable in 
situations involving larger areas of mucosa that would not otherwise be amenable to 
standard, targeted therapies, particularly on antithrombotic therapy. One can 
speculate, that a direct use of Hemospray without preceding established methods like 
heaterprobe, clips etc. might be cost-effective in particular clinical settings. Future 
multicenter randomized prospective trials are needed to increase the generalizability 
of case series. 
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Figure legend 
 
Figure 1a: Oozing bleeding after insertion of a percutaneous endoscopic gastrostomy 
tube (15 Charriere). Epinephrine and Beriplast was injected but failed hemostasis. 
Figure 1b: Successful hemostasis after Hemospray application.  
 
Figure 2a: Spurting ulcer bleeding (Forrest Ia) in the duodenum.  
Figure 2b: CoagGrasper did not reach hemostasis. After Hemospray application 
successful hemostasis. 
 
 
